Galectin Therapeutics Inc
Ownership
Ownership Structure
Who owns Galectin Therapeutics Inc (GALT)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 47.4% of the shares are freely tradable; institutional investors hold 21.2%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 1.95 | 1,966,542 | +0.0 | 03/31/2026 |
| Marshall Wace Asset Management Ltd | 1.21 | 1,219,912 | +102.6 | 03/31/2026 |
| Advisor Group Holdings, Inc. | 1.11 | 1,122,670 | +2.9 | 03/31/2026 |
| BlackRock Inc | 0.79 | 799,237 | +0.3 | 03/31/2026 |
| Sontag Advisory LLC | 0.72 | 721,788 | +0.0 | 06/30/2026 |
| Geode Capital Management, LLC | 0.61 | 612,786 | +2.5 | 03/31/2026 |
| Susquehanna International Group, LLP | 0.55 | 555,702 | +93.7 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.51 | 1,521,443 | +0.0 | 07/31/2026 |
| iShares Russell 2000 ETF | 1.04 | 1,046,053 | -0.6 | 08/31/2026 |
| Vanguard Institutional Extnd Mkt Idx Tr | 0.61 | 618,821 | +4.0 | 07/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Uihlein Richard E | Director | 44,713,843 | 165,441,219 $ | Jul 31, 2026 | indirect |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 31, 2026 | Uihlein Richard E | Director | Other | 2,550,932 | 4.05 | 10,331,275 |
| Jul 31, 2026 | Uihlein Richard E | Director | Other | 31,825,235 | 3.00 | 95,475,705 |
| Jul 14, 2026 | Jamil Khurram | Chief Medical Officer | Sell | 16,250 | 5.13 | 83,285 |
| Jul 14, 2026 | Jamil Khurram | Chief Medical Officer | Other | 16,250 | 3.04 | 49,400 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.